Proximal spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, with a carrier frequency of 1 in 35 in the population of mixed European descent and an incidence of approximately 1 in 6,000–10,000 live births (1, 2). This autosomal recessive neurodegenerative disorder is most commonly caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene, leading to reduced levels of ubiquitin-like modifier activating enzyme 1 (UBA1). SMN physically interacted with UBA1 in neurons, and disruption of Uba1 mRNA splicing was observed in the spinal cords of SMA mice exhibiting disease symptoms. Pharmacological or genetic suppression of UBA1 was sufficient to recapitulate an SMA-like neuromuscular pathology in zebrafish, suggesting that UBA1 directly contributes to disease pathogenesis. Dysregulation of UBA1 and subsequent ubiquitination pathways led to β-catenin accumulation, and pharmacological inhibition of β-catenin robustly ameliorated neuromuscular pathology in zebrafish, Drosophila, and mouse models of SMA. UBA1-associated disruption of β-catenin was restricted to the neuromuscular system in SMA mice; therefore, pharmacological inhibition of β-catenin in these animals failed to prevent systemic pathology in peripheral tissues and organs, indicating fundamental molecular differences between neuromuscular and systemic SMA pathology. Our data indicate that SMA-associated reduction of UBA1 contributes to neuromuscular pathogenesis through disruption of ubiquitin homeostasis and subsequent β-catenin signaling, highlighting ubiquitin homeostasis and β-catenin as potential therapeutic targets for SMA.
The iTRAQ screen revealed robust disruption of the synaptic proteome in SMA mice, where 52 out of 150 (35%) unique proteins identified had expression levels modified by more than 20% compared with littermate controls (Supplemental Tables 1 and 2). Functional clustering analyses, using IPA software (see Methods), linked these individual protein changes to significant modifications in a range of canonical functional pathways (Table 1). Interestingly, these analyses highlighted significant disruption to protein ubiquitination pathways in SMA mice, with decreased levels of UBA1 (Supplemental Figure 3A) and increased levels of ubiquitin carboxyterminal esterase L1 (UCHL1) (Table 1 and Supplemental Tables 1 and 2). Ubiquitination pathways, and UBA1 in particular, were of interest in the context of SMA because mutations in the gene coding for human UBA1 (UBE1) are sufficient to cause a genetically distinct form of the disease, known as X-linked infantile SMA (22). Moreover, ubiquitination pathways are known to regulate axonal and synaptic stability (27) as well as the stability and degradation of the SMN protein itself (28–30).

To establish whether disruption of ubiquitin-dependent pathways was conserved across the range of cells and tissues present in the neuromuscular system, UBA1 protein levels were examined in preparations of spinal cord (Figure 1, A and B, and Supplemental Figure 3B) and skeletal muscle (Figure 1, A and C) from severe SMA mice. UBA1 protein levels were reduced approximately 50% in preparations of spinal cord (Figure 1, A and B, and Supplemental Figures 1 and 2) and skeletal muscle (Supplemental Figures 1 and 2) and confirmed the biological relevance of using synaptic preparations for the initial proteomics screen. The iTRAQ screen revealed robust disruption of the synaptic proteome in SMA mice, where 52 out of 150 (35%) unique proteins identified had expression levels modified by more than 20% in SMA mice (Supplemental Tables 1 and 2). Functional clustering analyses, using IPA software (see Methods), linked these individual protein changes to significant modifications in a range of canonical functional pathways (Table 1). Interestingly, these analyses highlighted significant disruption to protein ubiquitination pathways in SMA mice, with decreased levels of UBA1 (Supplemental Figure 3A) and increased levels of ubiquitin carboxyterminal esterase L1 (UCHL1) (Table 1 and Supplemental Tables 1 and 2). Ubiquitination pathways, and UBA1 in particular, were of interest in the context of SMA because mutations in the gene coding for human UBA1 (UBE1) are sufficient to cause a genetically distinct form of the disease, known as X-linked infantile SMA (22). Moreover, ubiquitination pathways are known to regulate axonal and synaptic stability (27) as well as the stability and degradation of the SMN protein itself (28–30).

To establish whether disruption of ubiquitin-dependent pathways was conserved across the range of cells and tissues present in the neuromuscular system, UBA1 protein levels were examined in preparations of spinal cord (Figure 1, A and B, and Supplemental Figure 3B) and skeletal muscle (Figure 1, A and C) from severe SMA mice. UBA1 protein levels were reduced approximately 50% in preparations of spinal cord (Figure 1B) and skeletal muscle (Figure 1, A and C) from severe SMA mice. UBA1 protein levels were reduced approximately 50% in preparations of spinal cord (Figure 1B) and skeletal muscle (Figure 1B) and more than 60% in skeletal muscle (gastrocnemius; Figure 1C) at P5.

UBA1 regulates the first stages of an enzymatic cascade in which ubiquitin molecules are ultimately conjugated to target proteins; therefore, disruption of UBA1 (alongside concomitant changes in other ubiquitin-related proteins such as UCHL1) would be predicted to affect overall ubiquitin homeostasis. To determine whether this occurred in SMA, we measured levels of ubiquitin in the spinal cords from severe SMA mice. Levels of both monomeric and multimeric ubiquitin were significantly decreased (Figure 1, D–F). SMN-dependent perturbations in ubiquitin homeostasis were also conserved across other species and tissues, as a dramatic redistribution of mono- and polyubiquitinated proteins was observed in striated muscle from an established Drosophila model of SMA (Figure 1G and ref. 31).

To determine the time course of UBA1 changes in SMA, we examined UBA1 expression in “Taiwanese” SMA mice, which display a milder phenotype than severe SMA mice (mean survival of 11 days compared with 5–6 days; ref. 32). We examined UBA1 protein expression in motor neuron cell soma located in the ventral horn of spinal cord at presymptomatic (P3) and early symptomatic (P7) stages of disease (Figure 1, H–J). In control mice, UBA1 was almost exclusively localized to the neuronal cytoplasm at P3, before undergoing a dramatic subcellular relocation to the nucleus by P7 (Figure 1, H and I). There was no overt difference in UBA1 localization in SMA mice at P3. However, at P7, we noted an almost complete absence of UBA1 from the motor neu-
Figure 1

Perturbations in UBA1 levels and ubiquitin homeostasis in mouse and Drosophila models of SMA.

(A–C) Significant reduction in levels of UBA1 protein in spinal cord and skeletal muscle from severe SMA mice at P5 compared with littermate controls (con), quantified using fluorescent Western blot ($n = 3$ mice/genotype; unpaired 2-tailed $t$ test). (D–F) Reduced levels of both monomeric and multimeric ubiquitin in the spinal cord of Taiwanese SMA mice at P10 (tubulin: loading control; $n = 3$ mice/genotype). (G) Representative confocal micrographs of striated muscle from WT and SMA Drosophila larvae immunolabeled with an antibody that recognizes monom polyubiquitinated proteins (green). Diffuse staining in muscle and muscle nuclei (stained with Hoechst, blue) of WT flies contrasted with a distinct lack of nuclear staining and increased perinuclear staining in SMA flies. Each panel in G is 75 $\mu$m in length. (H and I) UBA1 (green) and NeuN (red) immunolabeling of motor neurons from Taiwanese SMA and littermate control mouse spinal cords at P3 (H) and P7 (I). Note how UBA1 was predominantly cytoplasmic at P3 but nuclear at P7. Scale bars: 10 $\mu$m. (J) Significant increase in the ratio of nuclear to cytoplasmic UBA1 in SMA motor neurons at P7 compared with littermate controls ($n = 24$ motor neurons per genotype). (K) UBA1 levels in whole spinal cord of Taiwanese SMA mice remained unchanged at P3 and P7, but were significantly reduced by P10 ($n > 3$ mice per time point/genotype; ANOVA with Tukey’s post-hoc test). (L) Levels of UBA1 in skeletal muscle were significantly reduced at an early symptomatic age (P7) in Taiwanese SMA mice ($n = 4$ mice per genotype). *$P < 0.05; **$P < 0.01; ***$P < 0.001.
UBA1 physically interacts with SMN protein in vivo, and \textit{Uba1} splicing is dysregulated at late symptomatic time points in SMA mouse spinal cord. (A) No change in levels of \textit{Uba1} mRNA (or a control mRNA, \textit{Fth1}; similar control data using \textit{Mapt} not shown) in the spinal cord of P5 severe SMA mice, quantified using qPCR \( (n = 3\) mice per genotype; ANOVA with Tukey’s post hoc test). (B) Representative fluorescent Western blots for SMN (left lane) and UBA1 (right lane) from co-IP experiments on spinal cord extracts from WT mice, using SMN-bound beads, demonstrating that UBA1 physically interacts with SMN in vivo. (C) Graphic overview of the exon structure of \textit{Uba1}. Two \textit{Uba1} splice variants are generated with unique first exons. The position of primers used to amplify each splice variant is highlighted. Note that the coding sequence of \textit{Uba1} starts in exon 2. (D–F) Bar charts showing relative expression levels of \textit{Uba1a} and \textit{Uba1b}, as well as the ratio of \textit{Uba1a} to \textit{Uba1b}, in SMA (Taiwanese) and control spinal cord at P3 (D; presymptomatic), P7 (E; early symptomatic), and P11 (late-symptomatic) \( (n = 3\) mice per genotype, 3 independent amplifications per sample; 2-tailed, unpaired \( t \) tests). \textit{Uba1} splicing was significantly dysregulated in the late-symptomatic mice. **\( P < 0.01; ***P < 0.001\).
ron cytoplasm in SMA mice, when low levels persisted in littermate control mice (Figure 1I). Quantification of the ratio of nuclear/cytoplasmic UBA1 levels in SMA mice revealed a significant reduction in the cytoplasm compared with controls (Figure 1J). Thus, redistribution of UBA1 occurring during the early postnatal period was perturbed in SMA mice at early symptomatic stages of the disease. Interestingly, quantification of total UBA1 levels in spinal cord did not reveal a significant reduction in SMA mice until late-symptomatic stages (P10; Figure 1K), suggesting that subtle changes in the subcellular distribution of UBA1 were perturbed in motor neurons in advance of a widespread reduction in protein levels throughout the spinal cord. Comparable examination of UBA1 levels in whole muscle showed a significant loss by P7 in SMA (Figure 1L), suggesting that muscle may be more severely affected than spinal cord.

**SMN-Uba1 interactions and dysregulation of Uba1 splicing in SMA.** To investigate potential pathways through which UBA1 and ubiquitin homeostasis are targeted in SMA, we first asked whether changes were occurring due to reduced expression of Uba1 mRNA. As mRNA levels for Uba1 remained unchanged in the spinal cords of SMA mice (Figure 2A), it was unlikely that UBA1 protein levels were reduced as a result of global deficiencies in transcription of Uba1 mRNA. Given that SMN protein interacts with other proteins in vitro, including members of the ubiquitin-proteasome system, we investigated potential pathways through which UBA1 and ubiquitin homeostasis are targeted in SMA.
Suppression of UBA1 is sufficient to induce motor neuron pathology in vivo. Although suppression of UBA1 and disruption of ubiquitin homeostasis were robust correlates of neuromuscular pathology in SMA, it remained unclear whether these changes directly contributed to disease pathogenesis. To examine this possibility, we designed experiments to suppress uba1 in zebrafish, an accessible model system to assess the effects of genetic manipulations on motor neuron stability (23, 33). Uba1 expression was targeted using an antisense Morpholino oligonucleotide (MO) designed against the translational start codon of the uba1 gene. Embryos were injected with either 4 ng or 6 ng of MO and examined 34 hours after fertilization. Levels of UBA1 protein were robustly reduced in fish treated at both doses (Supplemental Figure 4A). Suppression of uba1 using MO had no effect on the gross development of motor neurons in the spinal cord (Figure 3A). However, uba1 suppression did lead to a profound, dose-dependent disruption of motor axon outgrowth and branching. Whereas the vast majority of axons in control animals showed a simple, unbranched morphology, axons in both 4 ng and 6 ng MO–injected animals revealed grossly abnormal branching patterns (Figure 3, A and B). These pathological events phenocopied motor axon defects observed in zebrafish models of SMA (23, 33). Thus, suppression of uba1 was sufficient to phenocopy SMA-like motor neuron pathology in vivo. In addition to the observed motor axon defects, uba1 suppression led to body axis defects in zebrafish, both following UBEI-41 treatment and following MO treatment (data not shown). However, the viability of the fish was not compromised, as there was not a significant increase in the number of fish dying after uba1 suppression.

SMN-dependent suppression of UBA1 leads to accumulation of β-catenin. Given that UBA1 is a key component of ubiquitination pathways through which substrate proteins are “tagged” for targeting to the proteasome, we therefore wanted to identify specific substrate proteins affected as a downstream consequence of the disruption to ubiquitin homeostasis in SMA. Perturbations in ubiquitin pathways are often associated with a failure to degrade target proteins, resulting in a characteristic accumulation within the cell. Reexamination of our original proteomics data set revealed that β-catenin levels were robustly increased, by more than 400%, in SMA mice (Table 1 and Supplemental Tables 1 and 2). Examination of β-catenin levels in freshly prepared synaptosomes from control (Smn+/+ SMN2tg/tg), heterozygous (Smn+/- SMN2tg/tg) and homozygous (Smn−/- SMN2−/−) severe SMA mice confirmed that increased levels of β-catenin corresponded to reduced levels of SMN protein in a dose-dependent manner (Figure 4A). β-catenin levels were also significantly increased in the spinal cords of Taiwanese SMA mice (Figure 4B and Supplemental Figure 6). Alongside changes in β-catenin levels, levels of stabilized β-catenin (ABC) were reduced in the spinal cord (Figure 4C and Supplemental Figure 5), and levels of transcription factor 4 (TCF-4), a key β-catenin–interacting protein required for activation of downstream response genes (35), were also significantly reduced (Figure 4D and Supplemental Figure 5). Importantly, β-catenin protein levels in muscle biopsy samples from SMA patients suggested that elevated levels were also a major feature of neuromuscular pathology in human patients (Figure 4I).

To confirm that increased levels of β-catenin were occurring downstream of perturbations in UBA1, we examined global β-catenin levels in zebrafish treated with 4 ng or 6 ng MO against uba1. β-Catenin levels were increased in a dose-dependent manner, reaching approximately 250% of control levels in zebrafish treated with 6 ng MO against uba1 (Figure 4E). To further confirm a link between UBA1 levels and the regulation of β-catenin in neurons, cultures of primary hippocampal neurons and NSC-34 motor neuron–like cells (36) were exposed to the UBA1 inhibitor UBEI-41 for 2 hours. UBEI-41 treatment led to a rapid and significant increase in levels of β-catenin in hippocampal neurons (−50%; Figure 4F), with an even more robust increase in β-catenin levels observed in NSC-34 cells (−90%; Figure 4F), suggesting that motor neurons were particularly susceptible to suppression of UBA1. To establish whether increased levels of β-catenin protein led to a corresponding increase in β-catenin signaling activity, we performed luciferase activity reporter experiments. β-Catenin activity was significantly increased in NSC-34 cells treated with UBEI-41 for 2 hours (Figure 4G). In order to ascertain whether such changes in β-catenin signaling activity could explain changes
β-Catenin is a downstream target of UBA1 and accumulates in SMA. (A) β-Catenin and SMN protein in spinal cord of severe SMA, heterozygous (Het), and littermate (con) mice at P5 (tubulin: loading control). (B–D) β-Catenin was increased in P10 Taiwanese SMA mouse spinal cord (n = 3 control mice, n = 4 SMA; unpaired 2-tailed t test), whereas stabilized β-catenin (ABC; C) and TCF-4, a β-catenin interacting protein required for activation (D), were both reduced (n = 3 CON, n = 3 SMA). (E) Increased β-catenin protein in zebrafish injected with 4 ng or 6 ng of a uba1 MO 48 hours after fertilization. (F) Increased β-catenin in rat hippocampal neurons and a motor neuron cell line (NSC-34) treated with 50 μM UBEI-41 (ANOVA with Tukey’s post-hoc test; n = 12 coverslips DMSO, n = 15 UBEI-41 hippocampal; n = 19 DMSO, n = 18 UBEI-41 NSC-34). (G) Increased β-catenin signaling activity in NSC-34 cells treated with 50 μM UBEI-41 measured with a luciferase reporter construct (n = 3 coverslips per treatment). (H) The majority of proteins modified in SMA synapses (66 out of 115 analyzed; see Supplemental Tables 1 and 2) are known β-catenin target genes identified by ChIP-Seq analyses. (I) Increased β-catenin protein in muscle biopsies from 3 human SMA patients (pooled data on right of dotted line). (J) Western blots for β-catenin (left panel; green) and ubiquitin (right panel; red) from co-IP experiments on synaptic extracts from 2 WT mice (L, ladder; M1, mouse 1; M2, mouse 2). Immunoblotting on the bound extract revealed the presence of ubiquitinated β-catenin (upper arrow). *P < 0.05; **P < 0.01; ***P < 0.001.
in levels of other proteins found to be altered in SMA synaptosomes, we compared our proteomics data set to published β-catenin ChIP-Seq data revealing potential downstream targets of β-catenin (37). This analysis revealed that the majority of proteins modified in SMA synapses (66 out of 115 analyzed) were also present in the ChIP-seq data (Figure 4H), indicative of them being putative β-catenin targets.

β-catenin is a known target of the ubiquitin-proteasome system (38), but we wanted to confirm that β-catenin was being ubiquitinated in neurons. We therefore performed IP experiments on protein isolated from synaptosomes generated from WT mice (as in our initial proteomics screen, where increased levels of β-catenin were identified) using either β-catenin beads or pan-ubiquitin beads. Western blotting with antibodies against β-catenin and ubiquitin demonstrated that ubiquitinated forms of β-catenin were present in neurons and their synaptic compartments (Figure 4J).

Inhibition of β-catenin signaling reverses UBA1-dependent destabilization of motor neurons. To test whether the UBA1-dependent effects on motor nerve branching we observed previously were mediated by downstream effects on β-catenin signaling pathways, we exposed zebrafish embryos treated with the UBA1 inhibitor UBEI-41 to quercetin, a plant-derived flavonoid that robustly inhibits β-catenin signaling pathways by disrupting transcriptional activity of the β-catenin–Tcf complex (39–41). Treatment of fish with motor neuron defects resulting from the addition of 50 μM quercetin ameliorated key markers of neuromuscular pathology in both invertebrate and vertebrate models of SMA. Given that pharmacological inhibition of β-catenin signaling with quercetin was sufficient to block motor axon defects resulting from targeting of UBA1, we next wanted to know whether pharmacological inhibition of β-catenin signaling would have similar beneficial effects on neuromuscular pathology in animal models of SMA. Treatment with 50 μM quercetin robustly and significantly reduced the incidence of both truncated motor axons and motor axon branching defects in SMA zebrafish (33), reducing levels of motor axon pathology back to those observed in healthy control animals (Figure 6, A–C). Similarly, quercetin treatment reversed morphological defects associated with the NMJ in a dose-dependent manner in an established Drosophila model of SMA (31), rescuing both synaptic bouton size and bouton density in the treated SMA flies (Figure 6, D–F). Thus, pharmacological inhibition of β-catenin signaling with quercetin ameliorated key markers of neuromuscular pathology in both invertebrate and vertebrate models of SMA.

Inhibition of β-catenin signaling ameliorates neuromuscular pathology, but not systemic pathology in SMA mice. Finally, we wanted to establish whether pharmacological inhibition of β-catenin signaling with quercetin could have a similar effect on disease phenotype in SMA mice. Taiwanese SMA mice and littermate controls were treated with 10 mg/kg quercetin daily (i.p. injection) from birth. A parallel group of mice received injections of DMSO vehicle only. Treatment with 10 mg/kg quercetin was well tolerated by healthy littermate controls (an increased dose of 50 mg/kg quercetin was found to have toxic effects after several days of administration) and had no significant detrimental effect on neuromuscular function in SMA mice at presymptomatic ages (P3; Figure 7A). In contrast, quercetin treatment significantly improved the performance of early and late-symptomatic SMA mice on the righting test (Figure 7A). Quercetin treatment ameliorated motor neuron cell body loss from the spinal cord (Figure 7, B and C), restored muscle fiber diameters of SMA mice to those of littermate control mice at late-symptomatic stages (P11; Figure 7, E and F), and also ameliorated NMJ pathology, restoring the average number of axonal inputs in SMA mice to the same levels observed in littermate controls.
Thus, as we previously observed in zebrafish and Drosophila models, pharmacological inhibition of \( \beta \)-catenin signaling with quercetin ameliorates neuromuscular dysfunction and pathology in SMA mice.

Quercetin-treated mice often appeared much healthier than their DMSO-treated counterparts at late symptomatic stages (Figure 7D), but treatment with quercetin did not increase survival (Figure 7I) or average body weight (Supplemental Figure 6). Examination of quercetin-treated mice postmortem revealed the presence of widespread gross organ defects previously reported in SMA mice (Figure 7J), where systemic pathology is known to target organs including the heart and liver (10, 14, 16). In order to examine the possible causes of this failure to ameliorate nonneuromuscular defects previously reported in SMA mice (Figure 7J), we quantified UBA1 levels in the heart and liver from late-symptomatic Taiwanese SMA mice and littermate controls. Levels of UBA1 in the heart and liver were reduced in SMA mice to a level similar to that observed in spinal cord (Figure 7K). Surprisingly, however, \( \beta \)-catenin levels were not significantly modified in the heart and liver (Figure 7H).

Thus, perturbations in \( \beta \)-catenin signaling pathways occurring downstream of disrupted ubiquitin homeostasis were restricted to the neuromuscular system and were not repeated in nonneuromuscular organs. This suggests that distinct mechanisms drive pathology in the neuromuscular system compared with other tissue and organ systems in SMA and may explain, at least in part, why pharmacological inhibition of \( \beta \)-catenin selectively ameliorated neuromuscular pathology in SMA mice.

Discussion

The studies described here were initiated to identify novel regulators of neuromuscular pathology in SMA. Using rodent, Drosophila, and zebrafish SMA models, we have revealed an important role for ubiquitin homeostasis, mediated largely via modifications in levels of UBA1. Suppression of UBA1 in SMA is likely to result from a complex series of events, including disruptions in both splicing of \( Uba1 \) mRNA and physical interactions between SMN and UBA1 protein in the cytoplasm. Experimental down-regulation of UBA1 expression was sufficient to generate motor neuron pathology in vivo, phenocopying the severe axonal defects

(Figure 7, G and H).
Figure 7
Pharmacological inhibition of β-catenin ameliorates neuromuscular, but not systemic, pathology in SMA mice. (A) Significant improvement on the righting test in early (P6) and late-symptomatic (P9) Taiwanese SMA mice (KO) treated with 10 mg/kg quercetin (Kruskal-Wallis test with Dunn’s post hoc; P3, n = 30 tests Het; n = 27 KO; n = 21 KOQ; P6, n = 31, Het; n = 28 KO; n = 27 KOQ; P9, n = 32, Het; n = 27 KO; n = 36 KOQ). (B and C) Reduced motor neuron loss from spinal cord of quercetin-treated SMA mice at P10. (D) Untreated (left) and a quercetin-treated (right) SMA mice at P10. (E and F) Amelioration of skeletal muscle fibre atrophy in the levator auris longus (LAL) muscle of quercetin-treated SMA mice at P10 (n = 8 muscles Het, n = 9 KO, n = 4 KOQ). (G and H) Reduced NMJ pathology (average number of axonal inputs per NMJ; multiply innervated NMJs are indicated by arrows) in the LAL muscle of quercetin-treated SMA mice at P10 (n = 8 muscles Het, n = 9 KO, n = 4 KOQ). (I) Survival curve for quercetin-treated SMA mice showing no significant difference compared with DMSO-treated controls (P = 0.9897, χ² test; n = 10 mice DMSO; n = 13 quercetin). (J) Hearts (top) and livers (bottom) from control, SMA (KO DMSO), and quercetin-treated SMA (KO quercetin) mice at P10 showing no improvement in gross pathology. (K and L) UBA1 levels were reduced in all tissues from SMA mice at P10, but β-catenin levels were only correspondingly increased in spinal cord (n > 3 mice per genotype; ANOVA with Tukey’s post-hoc). Scale bars: 200 μm (B), 25 μm (E and G), 5 mm (J). *P < 0.05; **P < 0.01; ***P < 0.001.
previously reported in zebrafish models of SMA (33). We identified β-catenin as a downstream target of UBA1/ubiquitination pathways in the neuromuscular system and showed a robust accumulation of β-catenin in SMA. Pharmacological inhibition of β-catenin signaling using quercetin ameliorated neuromuscular pathology caused by targeting of UBA1 and in zebrafish, Drosophila, and mouse models of SMA. Whereas disruption of UBA1 was found to occur across a range of neuronal and nonneuronal organs in SMA mice, surprisingly, we found that downstream disruption of β-catenin was restricted to the neuromuscular system and was not responsible for regulating SMN-dependent pathology in other tissues and organs. Our findings provide experimental evidence directly linking the regulation of ubiquitin homeostasis and β-catenin signaling to neuromuscular pathology in SMA and also reveal fundamental molecular differences between pathways underlying neuromuscular and systemic pathology in SMA.

Although it is known that SMN protein interacts with the ubiquitin-proteasome system in order to regulate its own stability (28–30), our study markedly extends our understanding of the importance of these interactions to include a direct role for dysregulation of ubiquitin homeostasis in the pathogenesis of SMA. When taken together with human genetic data showing that mutations in UBA1 cause pathological changes similar to those found in SMN-dependent SMA (22), our findings suggest that perturbations in ubiquitin homeostasis, and UBA1 in particular, may represent a common molecular pathway underlying neuromuscular pathology across genetically distinct forms of the disease. Moreover, the finding that perturbations in ubiquitin homeostasis in response to SMN deficiency as well as dysregulation of β-catenin downstream of perturbations in UBA1 are evolutionarily conserved among mouse, zebrafish and Drosophila models suggests that regulation of ubiquitin homeostasis represents a core response to low levels of functional SMN protein. Our finding that loss of UBA1 protein in SMA likely resulted from perturbations to both Uba1 mRNA missplicing and disruption to physical interactions between SMN and UBA1 as well as modifications to normal postnatal subcellular redistribution of the protein suggests that molecular pathways responsible for controlling UBA1 levels in vivo are complex and multifaceted. However, the demonstration of interactions between UBA1 and SMN provides additional evidence to support the hypothesis that interactions between SMN and ubiquitination pathways are key for the normal form and function of the neuromuscular system, not only with regards to the regulation of SMN protein stability (28–30), but also with respect to modulating ubiquitin homeostasis and cell viability.

Our identification of β-catenin as a key downstream target of ubiquitin pathways disrupted in SMA provides mechanistic insights into the pathways through which defects in ubiquitin homeostasis are transferred into pathological changes in the neuromuscular system. Although these pathways have not previously been linked to neuromuscular pathology in SMA, β-catenin signaling pathways are known to play an important role in regulating motor neuron differentiation and stability, including regulating synaptic structure and function (42–44). Interestingly, Li and colleagues previously reported that motor neuron differentiation is regulated by retrograde signaling through β-catenin from skeletal muscle (43). Our demonstration of robust amelioration of neuromuscular pathology in zebrafish, Drosophila, and mouse models of SMA treated with quercetin highlights the fact that β-catenin pathways in the neuromuscular system are amenable to pharmacological targeting in vivo. It should be noted, however, that quercetin is a pleiotropic flavonoid and as such is capable of modifying targets alongside β-catenin pathways. Nevertheless, targeting β-catenin signaling pathways (in addition to other pathways modulated by quercetin) during the early stages of disease may represent an attractive therapeutic option for stabilizing the neuromuscular system in SMA, and possibly also related conditions.

Given that β-catenin is such a well-established target for the ubiquitin-proteasome system and the magnitude of changes in β-catenin pathways observed in the neuromuscular system in SMA mice, it was surprising to find that quercetin treatment did not target systemic pathology in SMA. However, our finding that β-catenin signaling pathways remained stable in tissues and organs outside the neuromuscular system in SMA mice provides an explanation for this result and serves to highlight an underappreciated complexity in molecular pathways underlying disease pathogenesis in SMA. These findings also add further significant support to the hypothesis that SMA is a multisystem disorder (10) and add an additional layer of complexity with regards to distinct molecular pathways driving pathology in different tissues. Moreover, they further highlight the likely requirement to deliver therapeutics targeting either the SMN1 or SMN2 gene systemically in order to fully rescue SMA symptoms (14).

Methods

Mice, human patient samples, and study approvals. Severe (Smn−/−; SMN2+/−; ref. 45) and Taiwanese (Smn−/−; SMN2+/−; refs. 32, 46) SMA mice, both on a congenic FVB background, were obtained from Jackson Laboratories and maintained at the University of Edinburgh. Littermate animals either WT or heterozygous for Smn (Smn+/− or Smn−/−) were used for controls. Mice were bred and sacrificed under license from the United Kingdom Home Office, and were genotyped using standard PCR methods (5, 32).

Skeletal muscle (quadriceps femoris) biopsy samples were obtained from 2 different biobanks in Italy (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, IRCCS, Milan) through EuroBioBank (http://www.eurobiobank.org/). Biopsies were obtained from 3 type II/III SMA patients (aged between 3 and 25 years old), with a confirmed homozygous deletion of the SMN1 gene confirming a genetic diagnosis of SMA (47). Three age-matched control samples were also obtained; these were genetically confirmed to have no mutations in the SMN1 gene.

iTRAQ quantitative proteomics. iTRAQ proteomics was performed on freshly isolated synaptosome preparations from the hippocampus of P1 Smn−/−; SMN2+ (severe) and Smn−/−; SMN2+ (control) mice (n = 9 mice per genotype), as previously described (48). Samples were run in duplicate using the 4-plex system (114 and 116, SMA; 115 and 117, control). Only proteins identified by 2 or more unique peptides were taken forward for subsequent analysis. A stringent cut-off threshold of 20% change (increase or decrease) was used to identify proteins with modified expression. In silico functional pathways analyses were performed using Ingenuity Pathway Analysis software (48).

Western blot analyses. Quantitative Li-Cor fluorescent Western blotting was performed as described (4) using the following primary antibodies: SMN, synaptoophysin (Santa Cruz Biotechnology Inc.); SMN, β-catenin (BD Biosciences); βIII tubulin, UBA1 (Abcam); histone H2B, active motif; Cox IV (MitoSciences); Ubiquitin (UBI1) (Millipore). Where required, 2 independent sets of measurements were produced per sample in order to minimize the effects of different laser scan intensities on the resulting data (e.g. where strong and weak bands were being measured on the same gel). Standard Western blotting was performed using the fol-
lowing primary antibodies: SMN: all MANSMA antibodies (49); gemin5: GEM5M, GEM5O, GEM5Q. All protein levels reported on graphs represent arbitrary fluorescence units.

**IP experiments.** IP was performed as previously described (50). Briefly, protein was extracted in NP-40 lysis buffer (Novex; Life Technologies) containing 1% protease inhibitor cocktail (Roche). Following centrifugation at 16000 × g, the supernatant was added to Dynabead protein G anti-mouse beads bound with preselected antibodies (β-catenin, UCHL1, and SMN) and subjected to quantitative fluorescent immunoblotting.

For Gemin5 IP experiments, anti-mouse Pan Ig–coated magnetic beads (50 μl) (Dynal) were washed in 4% BSA/PBS and incubated for 30 minutes with a monoclonal SMN antibody (10 μg; MANSMA12), GEM5M antibody against Gemin 5, or 150-kDa neurofilament antibodies as a control. After washing, beads were incubated with synaptosome extract for 1 hour, followed by washing 5 times with PBS. Proteins bound to beads were eluted by boiling in 2x SDS sample buffer, as previously described (51).

RNA extraction, qPCR, and Uba1 splicing assays. mRNA was extracted from synaptosomes using an RNasey Microkit (QIAGEN). Samples were checked for DNA contamination, and concentration was determined using a nanodrop spectrophotometer (Thermo Scientific). Quantitative RT-PCR (qRT–PCR) was carried out using a SYBR Green 1-step qRT-PCR Kit (Invitrogen) on a Model 7700 instrument (Applied Biosystems). The following primers were used: Uba1, forward GAGCGGGGACTTTGTCTCCT; reverse ATCTTGAACCTGTGAGGCAT; Uba1, reverse GACCCACTGGTGCACT; Mapt, forward GATCTCTGAGTGTTGGAC; Mapt, reverse TACGAGAAAGAAGCCAGATT.

mRNA was extracted from spinal cord using an RNasey Microkit (QIAGEN). Samples were checked for DNA contamination, and concentration was determined using a nanodrop spectrophotometer (Thermo Scientific). RNA integrity was checked visually by resolution on agarose gels. cDNA was made from 2 μg RNA using the High Capacity cDNA Reverse Transcription Kit (Invitrogen). Primers were designed that amplified the 2 mouse Uba1 transcripts, using a unique forward primer with a common reverse primer (Uba1a, forward GCTTGTCTCCAGAAGGAAAG; Uba1b, forward CCTGACCTCGGCTCTTTGAGG; Uba1b/ub, reverse CACTGAGGACACTTCCGGACA). Two mouse housekeeping genes (GAPDH and OAZI) were used (GAPDH, forward GTCCCTCGTACAAATGGGT; GAPDH, reverse GAATTGCGGTAGTTGGGA; OAZI, forward ATCTCTCAACGACCTGCT; OAZI, reverse CGGACCCAGTTACACAG). For real-time detection, an ABI7900 machine (Applied Biosystems) was used. cDNA was amplified using 0.5 to 1 μM primer with the DyNaFlash Sybr Green qPCR kit (Thermo Scientific) and using a standard PCR program with amplification at 60°C. Each cDNA sample was amplified in triplicate with all primer pairs. Experimental CT values for each sample were compared, and samples representing the same mean for each primer pair were identified. The equation where raw data = 1 + E^{C_{T}−C_{T}−}\text{MO}\text{MO} was used to determine relative expression levels for each sample. Raw values obtained for Uba1a and Uba1b were normalized using the geometric mean of the 2 housekeeping genes.

**Drosophila experiments.** To examine localization of SMN, pan-neuronal expression of UAS-YFP-dSMN was driven by Elav-Gal4 (51). McLarenGal4 crossed to UAS-YFP-dSMN flies were used as controls. Wandering third instar larvae were dissected in PBS and fixed for 10 minutes in 4% paraformaldehyde. GFP staining at NMJs was detected by blocking larval fillets in 3% BSA, 0.1% Triton X-100 in PBS overnight, incubating in primary antibody, 1:400 (chicken anti-GFP, A10262, Invitrogen), followed by secondary antibody, 1:250 (goat anti-chicken Alexa Fluor 488; A11039, Invitrogen). NMJs and motor neurons were visualized with Dylight 649–conjugated anti-HRP, 1:200 (Jackson ImmunoResearch). Images were acquired on a Zeiss LSM510 Meta using a Pan Apochromat 63× 1.4 NA oil immersion objective. To examine levels of mono- and polyubiquitinated proteins in SMA skeletal muscle, we used wandering third instar larvae null for SMN (31). Ubiquitinated proteins were detected using an anti-mono- and polyubiquitinylated primary antibody (1:100; FK2; BML-PW8110, Enzo Life Sciences). Nuclei were visualized using Hoechst (1:500). For the quercetin rescue experiments, SMN or WT flies (w^{1188}B) were maintained on a diet of Drosophila Quick Mix Medium (Blades Biological) containing 0 to 50 μM quercetin hydrate (Sigma-Aldrich). Third instar smn null larvae were dissected and fixed. NMJ were visualized using Dylight 649–conjugated anti-HRP (1:200, Jackson ImmunoResearch), and the presynaptic marker cysteine string protein (1:200, Developmental Studies Hybridoma Bank) was used to identify synaptic boutons. The average number of boutons (normalized to muscle area) per NMJ at muscle 6/7 was calculated. Maximum bouton diameters were averaged per NMJ at muscle 6/7.

**UBEI-41 in vitro experiments.** Primary rat hippocampal cultures were established from E18 Sprague-Dawley rat embryos as previously described (52); NSC-34 cells (36) were generated from existing stocks held at the University of Edinburgh. UBEI-41 (Biogenova), a cell-permeable UBA1 inhibitor with an IC_{50} of approximately 5 μM, was added to the culture medium (50 μM) for 2 hours. β-catenin levels (and β-III tubulin loading control levels) were quantified using fluorescent Western blotting (see above) with anti-β-catenin (1:1000; BD Transduction Laboratories) and anti-β-III tubulin (1:1600; Abcam) primary antibodies.

To quantify β-catenin activity, NSC-34 cells were transiently transfected with a TOPflash reporter plasmid containing a luciferase reporter under the control of 3 copies of the TCF/LEF-binding element upstream of the thymidine kinase minimal reporter, specifically regulated by Wnt/β-catenin signaling. NSC-34 cells were seeded in a 24-well plate, and at 70%-80% confluency, cells were transfected in triplicate, with 350 ng TOPflash plasmid using Lipofectamine 2000 (Invitrogen). To control for transfection efficiency, 20 ng pHTKRenilla luciferase plasmid was used. Cells were treated with 50 μM UBEI-41 28 hours after transfection. Transfected samples were analyzed for firefly and Renilla luciferase activities 30 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega) and measured using a FLUostar OPTIMA Microplate Reader (BMG LABTECH). All values were corrected to blank wells and normalized to expression from the pHTKRenilla plasmid.

**Zebrafish uba1 and smn knockdown.** An antisense MO was designed against the translational start codon of the uba1 gene (Gene Tools LLC): 5′-ACAGCG- GGCGAGCTGGACATCGTTTC-3′. The previously published smn-MO was designed against the 5′ start sequence of the smn gene (Gene Tools LLC); 5′-CGACATCTTCTGCACCATGGCC-3′ (33). Zebrafish embryos were injected between the 1- and 4-cell stage. For direct evaluation of motor axon phenotype, we used embryos obtained from crossing TL/EK WT and Tg(mnx:GFP)tm2 transgenic animals (53). Embryos were injected with either 4 or 6 ng of uba1-MO or 4 ng of smn-MO in aqueous solution containing 0.05% phenol red and 0.05% rhodamine-dextran. Six hours after injection, embryos were sorted according to homogeneity of rhodamine fluorescence, reflecting equal distribution of the injected MO solution. Quercetin (Sigma-Aldrich) treatment was performed at 6 hpf. In brief, quercetin solution (in DMSO) or DMSO (Sigma-Aldrich) was added to buffered embryo medium (final volume: 2 μl/assay/ml medium) to obtain a final concentration of 50 μM. For immunostaining, fish (34 hpf) were dechorionated and fixed in 4% PFA overnight, dehydrated in methanol, rehydrated, and washed in PBS. After collagenase treatment (1 μg/ml; C-9891, Sigma-Aldrich) for 10 minutes at room temperature, embryos were blocked in PBST plus 1% FCS, followed by overnight incubation in 500 μl blocking solution containing monoclonal mouse anti-zebrafish Synaptotagmin (znp-1) antibody (1:300; Developmental Studies Hybridoma Bank). After washing, fish were incubated in donkey anti-mouse secondary antibody labeled with
Alexa Fluor 488 (1:200; Invitrogen). Microtissue analysis was performed in 80% glycerol on micro slides using an Axioskop 2 fluorescence microscope (Zeiss). The length of each of the first 10 motor axons behind the yolk was analyzed and evaluated, as was the extent of abnormal branching (Supplemental Figure 4).

Zebrafish UBE1-41 experiments. UBE1-41 (BioGenova), on its own or with quercetin (Sigma-Aldrich), was dissolved in DMSO and added at 6 μM to Tg(mnx:GFP)224. The final amount of DMSO in the test groups was always 2 μl/μl in buffered embryo medium. Western blots were performed using the following antibodies: anti–β-actin (zebrafish) (rabbit polyclonal, 1:1,000; Anaspec); anti-UBA1 (mouse monoclonal, 1:1,000; Santa Cruz Biotechnology Inc.); anti–rabbit-HRP (1:10,000; GE Healthcare); anti–mouse-HRP (1:10,000; Sigma-Aldrich); anti–β-catenin (polyclonal rabbit, 1:1,000, C2206; Sigma-Aldrich). At 27 hpf, embryos were dechorionated, fixed in 4% PFA for 2 hours, and mounted in 70% glycerol. Motor nerves were assessed for abnormal trajectories using a Zeiss Axioscope A1 fluorescence microscope, and image stacks were taken using a Zeiss LSM710. For each embryo, 24 axons in 12 segments were analyzed. The observer was always blinded to the treatment.

SMA mouse quercetin experiments. Taiwanese mice and littermate controls were dosed daily with either 10 mg/kg quercetin (Sigma-Aldrich) or DMSO alone for a vehicle-only control via intraperitoneal injection. Mice were randomly assigned to treatment groups. Righting reflex tests were performed in order to assess neuronal function, as previously described (54). Muscle fibre diameter measurements were taken from phase-contrast micrographs of teased muscle fiber preparations using ImageJ software, as previously described (4). Motor neuron cell body counts were performed as previously described (32). NMJ pathology was assessed on whole-mount preparations of levator auris longus muscles, as previously described (5). Kaplan-Meier survival analyses were performed on DMSO and quercetin-treated mice as previously described (55). Organs were dissected and either fixed in 4% paraformaldehyde overnight for subsequent imaging, or were prepared for quantitative Western blotting.

Study approval. All required ethical approvals to acquire and distribute human patient tissue samples were obtained by the host biobanks. Tissue was provided in an anonymous fashion, with no identifying details apart from the age, sex, and genetic status of the patient. All animal studies were approved by the internal ethics committee at the University of Edinburgh and were performed under the authority of relevant project and personal licenses from the United Kingdom home office.

Statistics. All graphs are shown as mean ± SEM. All statistical analyses were completed using GraphPad Prism software. P < 0.05 was considered statistically significant for all analyses.

Acknowledgments

The authors are grateful to Nils Lindstrom and members of the Gillingwater laboratory for advice and assistance with this study and helpful comments on the manuscript; Neil Cashman for the NSC-34 cell line; and Ji-Long Liu for the Drosophila smn1 and smn4 lines. This work was supported by grants from the SMA Trust (to T.H. Gillingwater, P.J. Young, and R. Morris), BDF Newlife (to T.H. Gillingwater and S.H. Parson), the Anatomical Society (to T.H. Gillingwater and S.H. Parson), the Muscular Dystrophy Campaign (to T.H. Gillingwater), the Jennifer Trust for Spinal Muscular Atrophy (to H.R. Fuller), the Muscular Dystrophy Association (to G.E. Morris), the Vandervell Foundation (to P.J. Young), the Medical Research Council (GOB2208 to I.M. Robinson), Roslin Institute Strategic Grant funding from the BBSRC (to T.M. Wishart), the BBSC (to C.G. Becker), the Deutsche Forschungsgemeinschaft and EU FP7/2007-2013 (grant no. 2012-305121, NeurOmics, to B. Wirth), the Center for Molecular Medicine Cologne (to B. Wirth and M. Hammerschmidt), and SMA Europe (to M.M. Reissland). We would also like to acknowledge financial support to the Gillingwater lab generated through donations to the SMASHSMA campaign.

Received for publication May 29, 2013, and accepted in revised form December 20, 2013.

Address correspondence to: Thomas H. Gillingwater, Euan MacDonald Centre for Motor Neurone Disease Research and Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, United Kingdom. Phone: 44.0.131.6503724; E-mail: T.Gillingwater@ed.ac.uk.


